MAP2K7 and non-small cell lung carcinoma: Since only a phase Ib study [56] investigated the safety and efficacy of cobimetinib plus atezolizumab in a single arm for few NSCLC patients and several PD-1/L1 inhibitors plus MEK inhibitors clinical trials [57] (Table 4) are still ongoing, the finial clinical outcomes are worthy being looking forward to furthermore.